

| Presentation | Vial: 50 mg <br> Infusion solution from Pharmacy |
| :--- | :--- |
| Description | Polyene antifungal |
| Indications | Treatment of invasive fungal infections by susceptible fungi including <br> Candida spp., Aspergillus spp. and Cryptococcus species. Candida <br> lusitaniae and A. terreus are resistant. |
| Dosage | IV: <br> Initial dose - 1mg/ kg/ dose |
| Interactions | Increased risk of nephrotoxicity if used concurrently with other <br> nephrotoxic drugs e.g. aminoglycosides, vancomycin. <br> Flucytosine toxicity may be enhanced <br> Corticosteroids and diuretics may enhance the hypokalaemic effect <br> of amphotericin B |
| Compatible <br> Fluids | Glucose 5\% |


| Preparation | IV: Available from CIVAS (KEMH \& PCH) <br> Step 1 - Reconstitution <br> Add 12mL of Water for Injection to 50mg vial. Shake for at least 30 <br> seconds. <br> Concentration =4mg/mL <br> Filter reconstituted solution using supplied filter, prior to dilution. <br> Step 2 - Dilution <br> Take 5mL (20mg) of above filtered solution and make up to 10mL <br> with Glucose 5\%. <br> Final concentration is 2mg/mL |
| :--- | :--- |
| Administration | IV Infusion: <br> Infuse over 60-120 minutes <br> IV line must be flushed with 5\% glucose before and after the dose |
| Monitoring | Urine output. Full blood count (FBC) for anaemia and <br> thrombocytopenia <br> Renal function (for elevated creatinine), electrolytes (for <br> hypokalaemia) and liver function (for derangements of liver <br> enzymes). <br> Monitor serum concentrations of concomitant nephrotoxic drugs. |
| Adverse | Common: nausea, vomiting, rash, fever, rigors <br> Reactions |
| Serious: hypokalaemia, hypomagnesaemia, hypocalcaemia, |  |
| nephrotoxicity, anaemia, thrombocytopenia |  |

## References

Ainsworth SB. Neonatal formulary 7: drug use in pregnancy and the first year of life. Seventh ed. Chichester (West Sussex): John Wiley \& Sons Inc.; 2015. p140
Takemoto CK, Hodding JH, Kraus DM. Pediatric \& neonatal dosage handbook with international trade names index: a universal resource for clinicians treating pediatric and neonatal patients. 24th ed. Hudson (Ohio): Lexicomp; 2401. 2, p141-142.
Truven Health Analytics. Amphotericin Liposomal. In: NeoFax [Internet]. Greenwood Village (CO): Truven Health Analytics; 2019 [cited 2019 Sept10]. Available from: https://neofax.micromedexsolutions.com/

Society of Hospital Pharmacists of Australia. Amphotericin Liposomal. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2019 [cited 2019 Sept10]. Available from: http://aidh.hcn.com.au

Lilley L, Legge D. Paediatric injectable guidelines. 5th ed. Melbourne (Victoria): The Royal Children's Hospital; 2019.

Paediatric Formulary Committee. BNF for Children: 2017. London: BMJ Group Pharmaceutical Press; 2017

| Keywords: | Amphotericin, liposomal, fungal, ambisome |  |  |
| :---: | :---: | :---: | :---: |
| Publishing: | 】 Intranet $\quad$ \Internet |  |  |
| Document owner: | Head of Department - Neonatology |  |  |
| Author / Reviewer: | KEMH \& PCH Pharmacy / Neonatology Directorate |  |  |
| Date first issued: | August 2002 | Version: | 3.0 |
| Last reviewed: | October 2019 | Next review date: | Oct 2022 |
| Endorsed by: | Neonatal Directorate Management Group | Date: | Oct 2019 |
| Standards Applicable: | NSQHS Standards: 1 Q Governance, 3 OInfection Control, 4 Medication Safety, 8 -Acute Deterioration |  |  |
| Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from the WNHS website. <br> For any enquiries relating to this guideline, please email KEMH.PharmacyAdmin@health.wa.gov.au |  |  |  |

© Department of Health Western Australia 2019

